presentation of fiscal 2006 first half results akira uehara president taisho pharmaceutical november 10 background to downward revision in october the business environment surrounding otc drugs has worsened further many specialist drug manufacturers and major drugstores are struggling mainstay brands lipovitan series sales drinks overall slumped due inclement weather intensification price competition time required for clearance distributors inventories especially food oriented channels with functional other products riup lateness developing new users s marketing organization was restructured april but it took more than initially assumed get underway summary fy2006 consolidated 1h fy06 yoy growth vs forecast net 122 0 12 3 9 7 5 operating income 14 43 8 recurring 16 4 38 6 2 21 eps yen 40 01 billions previous announced july factors driving decline product brand bn market contraction pabron
